Abstract Library

#1637 The Effect of the Autophagy Inhibitor Chloroquine (CQ), Alone or in Combination with mTOR Inhibitors, on Neuroendocrine Tumor (NET) Growth and Metastatic Spread in Mouse Models

Introduction: mTOR inhibitors (mTORi) such as RAD001 demonstrated promising anti-cancer effect in NETs. Autophagy, a cell survival mechanism, is activated by mTORi. We have recently shown in the human NET cell line BON1 that autophagy is essential for cell survival. Treatment with CQ alone or together with mTORi robustly inhibited cell proliferation and survival, suggesting that treatment with CQ may potentiate the anti-tumorigenic effects of mTORi.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Avniel-Polak S

Authors: Avniel-Polak S, Leibowitz G, Gross D, Grozinsky-Glasberg S,

Keywords: autophagy, mTORi, NET,

#1163 Mitotane, Adrenolitic Drug, Inhibits Cell Survival and Function of Several Pituitary Cytotypes

Introduction: Mitotane (DDD) is an adrenolytic agent that is used for the treatment of adrenocortical carcinoma. We previously demonstrated that DDD affects thyrotrope cell viability and function. These data represent a possible explanation of the biochemical picture consistent with central hypothyroidism in patients undergoing DDD therapy. DDD also inhibits corticotrope cell viability by inducing caspase-mediated apoptosis and reduces POMC expression as well as basal and CRH-induced ACTH secretion. Cells originating from tissues different from pituitary are not sensitive to the inhibitory effects of DDD. Our data suggest that DDD inhibits cell survival and function of many pituitary cytotypes, acting with a generalized, but specific, toxic effect. The majority of male patients undergoing adjuvant DDD therapy show a clinical picture of hypogonadism, characterized by low free testosterone and unmodified LH concentration

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Gentilin E

Authors: Gentilin E, Gagliano T, Benfini K, Di Pasquale C, Falletta S,

Keywords: mitotane, adrenocortical cancer, pituitary,

#833 The Chemokine Receptor CXCR4 – Differential Expression in Bronchopulmonary Neuroendocrine Neoplasms

Introduction: The CXCR4 is a plasma membrane chemokine receptor, which is involved in organogenesis, hematopoiesis and inflammation. Additionally, an over-expression is described for many neoplastic tissues. Here, an involvement in tumor progression, metastasis, adaptation to hypoxia and in stem cell survival is postulated.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Reimann C

Authors: Reimann C, Kaemmerer D, Specht E, Wirtz R, Lupp A,

Keywords: neuroendocrine, tumor, SCLC, CXCR4, IHC,

#815 The Effect of Autophagy Inhibitors Alone or in Combination with mTOR Inhibitors in a Neuroendocrine Tumor Cell Model

Introduction: Most patients with neuroendocrine tumors (NETs) require systemic treatment, often with a limited therapeutic effect. RAD001 and Torin1 are mTOR inhibitors (mTORi) known to suppress cell proliferation in NETs. However, cancer cells may use mTORi-induced autophagy to escape the anti-proliferative effect and to prolong cell survival. Chloroquine (CQ) and hydroxychloroquine (HCQ) inhibit autophagy.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Glasberg S

Authors: Avniel-Polak S, Leibowitz G, Glaser B, Gross D, Glasberg S,

Keywords: NETs, autophagy, mTOR inhibitors,

#789 Ovriectomy

Introduction: Bilateral OVX in female rats cause neurodegeneration in the nervous system of rodents and imitates systemic disorders in postmenopausal women. Synaptic modulation by estrogen is essential to understanding the molecular mechanisms of estrogen replacement therapy.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Simonyan K

Authors: Simonyan K,

Keywords: Sinestrol, hippocamp, synaptic activity, phosphatase activity,